quinta-feira, 12 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

Is Most-Watched Stock Target Corporation (TGT) Worth Betting on Now?

View original at finance.yahoo.com
Is Most-Watched Stock Target Corporation (TGT) Worth Betting on Now? Target (TGT) has been one of the most searched-for stocks on Zacks.com lately…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Target is expected to post earnings of $2.21 per share for the current quarter, indicating a change of +7.8% from the year-ago quarter

    60% confidence
  • The Zacks Consensus Estimate for Target's current quarter has changed -0.4% over the last 30 days

    60% confidence
  • Target shares returned -2.8% over the past month versus the Zacks S&P 500 composite's +4.8% change, while the Zacks Retail - Discount Stores industry gained 0.6%

    60% confidence
  • The consensus earnings estimate of $8.28 for Target's current fiscal year points to a change of +9.4% from the prior year

    60% confidence
  • Empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements

    60% confidence
  • The next fiscal year consensus EPS estimate for Target has changed +3.8% over the past month

    60% confidence
  • Target receives a Zacks Rank #3 (Hold), driven by the size of recent consensus estimate change and three other earnings-estimate-related factors

    60% confidence
  • The current fiscal year consensus EPS estimate for Target has changed +4.1% over the last 30 days

    60% confidence
  • The consensus earnings estimate of $8.80 for Target's next fiscal year indicates a change of +6.3% from what Target is expected to report a year ago

    60% confidence

Data points we hold from this source

Target Corporation · eps+7.8 percent_yoy
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com